Pfizer (NYSE:PFE) Shares Up 0.2% - What's Next?

Pfizer Inc. (NYSE:PFE - Get Free Report)'s share price traded up 0.2% during mid-day trading on Friday . The stock traded as high as $25.08 and last traded at $25.06. 8,885,026 shares changed hands during trading, a decline of 76% from the average session volume of 36,714,311 shares. The stock had previously closed at $25.01.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on PFE shares. Citigroup dropped their target price on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. UBS Group cut their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Bank of America reissued a "neutral" rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. Finally, Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Pfizer currently has an average rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Price Performance

The stock has a 50 day moving average of $26.06 and a 200-day moving average of $26.90. The stock has a market capitalization of $143.80 billion, a P/E ratio of 17.98, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 earnings per share. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.06% of the company's stock.

Hedge Funds Weigh In On Pfizer

Several institutional investors have recently made changes to their positions in PFE. Retirement Wealth Solutions LLC purchased a new position in Pfizer during the 4th quarter valued at about $26,000. Rialto Wealth Management LLC purchased a new position in Pfizer during the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. bought a new position in Pfizer in the fourth quarter worth approximately $27,000. Gould Capital LLC lifted its holdings in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the period. Finally, Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer during the 4th quarter valued at $28,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.